Quantcast

Latest Macular edema Stories

2014-09-16 08:29:26

Regeneron plans to submit sBLA for this indication by year end TARRYTOWN, N.Y., Sept. 16, 2014 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has granted EYLEA(®) (aflibercept) Injection Breakthrough Therapy designation for the treatment of diabetic retinopathy in patients with diabetic macular edema (DME). The designation is based on positive results in two Phase 3 trials (VIVID-DME and VISTA-DME), in which...

2014-09-04 04:21:42

TARRYTOWN, N.Y., Sept. 4, 2014 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that Bayer HealthCare's Japanese subsidiary, Bayer Yakuhin, Ltd. has submitted a marketing authorization application for EYLEA(®) (aflibercept) Injection for macular edema following branch retinal vein occlusion (BRVO) to the Japanese Ministry of Health, Labour and Welfare (MHLW). EYLEA has already been approved in Japan for the treatment of patients with neovascular (wet)...

2014-09-03 20:23:43

MarketOptimizer.org adds new report "Epicast Report: Diabetic Macular Edema - Epidemiology Forecast to 2023" to its store. DALLAS, Sept. 3, 2014 /PRNewswire-iReach/ -- Macular edema (ME) occurs due to the thickening and swelling (edema) of the macula, which is the area of the retina that is responsible for central vision. In ME, fluid and protein deposits collect on or under the macula of the eye, due to a breakdown in the blood-retinal barrier. The occurrence of ME is highly frequent in...

2014-08-11 04:21:54

TARRYTOWN, N.Y., Aug. 11, 2014 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that EYLEA(®) (aflibercept) Injection has been approved by the European Commission for the treatment of visual impairment due to Diabetic Macular Edema (DME). Bayer Healthcare plans to launch EYLEA in DME in the EU this quarter. "DME is the leading cause of vision loss in working-age adults in much of the developed world, and we believe EYLEA will be an important new treatment...

2014-07-29 20:23:16

DME is the third approved indication for EYLEA in the U.S. TARRYTOWN, N.Y., July 29, 2014 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has approved EYLEA(®) (aflibercept) Injection for the treatment of Diabetic Macular Edema (DME). The recommended dosage of EYLEA in patients with DME is 2 milligrams (mg) every two months (8 weeks) after five initial monthly injections. Although EYLEA may be dosed as...

2014-07-18 08:23:16

TARRYTOWN, N.Y., July 18, 2014 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that in the Phase 3 VIVID-DME trial of EYLEA(®) (aflibercept) Injection for the treatment of diabetic macular edema (DME), EYLEA 2 milligrams (mg) dosed monthly (2Q4) and EYLEA 2 mg dosed every two months (after 5 initial monthly injections, 2Q8) showed a sustained improvement from baseline in best corrected visual acuity (BCVA) at week 100 (2 years), compared to laser...

2014-07-14 23:03:57

The Retina Group of New York (RGONY), with offices in Hicksville and Hauppauge, NY, has announced the availability of Ozurdex® (dexamethasone intravitreal implant) as a long-lasting treatment for diabetic macular edema (DME) patients. Hicksville and Hauppauge, NY (PRWEB) July 14, 2014 The Retina Group of New York (RGONY), with offices in Hicksville and Hauppauge, NY, has announced the availability of Ozurdex® (dexamethasone intravitreal implant) as a long-lasting treatment for...

2014-06-27 08:24:46

TARRYTOWN, N.Y., June 27, 2014 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that EYLEA(®) (aflibercept) Injection has been recommended for approval by the European Committee for Medicinal Products for Human Use (CHMP) for the treatment of visual impairment due to diabetic macular edema (DME). The decision of the European Commission is expected in the second half of 2014. "Diabetes is a growing health concern worldwide and this milestone brings us...

2014-06-11 04:21:59

TARRYTOWN, N.Y., June 11, 2014 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Bayer HealthCare today announced that Bayer HealthCare has submitted an application to the European Medicines Agency (EMA) seeking marketing authorization in the European Union (EU) for EYLEA(®) (aflibercept) Injection for the treatment of macular edema following branch retinal vein occlusion (BRVO). The EMA submission is based on the positive Phase 3 VIBRANT trial, a double-masked,...

2014-06-09 08:29:08

VANCOUVER, June 9, 2014 /PRNewswire/ - iCo Therapeutics Inc. ("iCo" or "the Company") (TSX-V: ICO) (OTCQX: ICOTF) today announced top-line results related to the eight month visual acuity (VA) primary endpoint for subjects enrolled in the Phase 2 iDEAL Study, conducted in collaboration with JDRF, evaluating the efficacy and safety after repeated injections of iCo-007 in patients with Diabetic Macular Edema (DME). Statistical methods employed included both Last Observation Carry...


Word of the Day
grass-comber
  • A landsman who is making his first voyage at sea; a novice who enters naval service from rural life.
According to the OED, a grass-comber is also 'a sailor's term for one who has been a farm-labourer.'